Literature DB >> 33432223

BTK blockers make headway in multiple sclerosis.

Elie Dolgin1.   

Abstract

Entities:  

Year:  2021        PMID： 33432223     DOI： 10.1038/s41587-020-00790-7

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  9 in total

Review 1.  Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis.

Authors:  Heather Y F Yong; V Wee Yong
Journal:  Nat Rev Neurol       Date:  2021-11-03       Impact factor: 42.937

Review 2.  The role of glial cells in multiple sclerosis disease progression.

Authors:  Luke M Healy; Jo Anne Stratton; Tanja Kuhlmann; Jack Antel
Journal:  Nat Rev Neurol       Date:  2022-02-21       Impact factor: 44.711

Review 3.  Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.

Authors:  Ewa Robak; Tadeusz Robak
Journal:  J Clin Med       Date:  2022-05-16       Impact factor: 4.964

4.  Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury.

Authors:  Chen Guang Yu; Vimala Bondada; Hina Iqbal; Kate L Moore; John C Gensel; Subbarao Bondada; James W Geddes
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 5.  The Development of BTK Inhibitors: A Five-Year Update.

Authors:  Bruno Tasso; Andrea Spallarossa; Eleonora Russo; Chiara Brullo
Journal:  Molecules       Date:  2021-12-06       Impact factor: 4.411

6.  Ibrutinib as a potential therapeutic for cocaine use disorder.

Authors:  Spencer B Huggett; Jeffrey S Hatfield; Joshua D Walters; John E McGeary; Justine W Welsh; Trudy F C Mackay; Robert R H Anholt; Rohan H C Palmer
Journal:  Transl Psychiatry       Date:  2021-12-08       Impact factor: 6.222

7.  Safety and efficacy of tyrosine kinase inhibitors for the treatment of multiple sclerosis: A systematic review and meta-analysis from randomized controlled trials.

Authors:  Zeya Yan; Feng Gu; Zilan Wang; Jiahao Meng; Xinyu Tao; Qiling Dai; Wei Wang; Meirong Liu; Zhong Wang
Journal:  Front Neurol       Date:  2022-09-26       Impact factor: 4.086

Review 8.  Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.

Authors:  Stefan F H Neys; Rudi W Hendriks; Odilia B J Corneth
Journal:  Front Cell Dev Biol       Date:  2021-06-04

9.  Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.

Authors:  Eris Bame; Hao Tang; Jeremy C Burns; Million Arefayene; Klaus Michelsen; Bin Ma; Isaac Marx; Robin Prince; Allie M Roach; Urjana Poreci; Douglas Donaldson; Patrick Cullen; Fergal Casey; Jing Zhu; Thomas M Carlile; Dipen Sangurdekar; Baohong Zhang; Patrick Trapa; Joseph Santoro; Param Muragan; Alex Pellerin; Stephen Rubino; Davide Gianni; Bekim Bajrami; Xiaomei Peng; Alex Coppell; Katherine Riester; Shibeshih Belachew; Devangi Mehta; Mike Palte; Brian T Hopkins; Matthew Scaramozza; Nathalie Franchimont; Michael Mingueneau
Journal:  Clin Transl Immunology       Date:  2021-06-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.